New Zealand markets close in 1 hour 57 minutes
  • NZX 50

    12,038.09
    +2.04 (+0.02%)
     
  • NZD/USD

    0.6502
    +0.0006 (+0.09%)
     
  • NZD/EUR

    0.5976
    +0.0005 (+0.09%)
     
  • ALL ORDS

    7,706.60
    -2.90 (-0.04%)
     
  • ASX 200

    7,487.10
    -6.70 (-0.09%)
     
  • OIL

    80.08
    +0.40 (+0.50%)
     
  • GOLD

    1,944.50
    -1.10 (-0.06%)
     
  • NASDAQ

    12,166.60
    +115.10 (+0.96%)
     
  • FTSE

    7,765.15
    +4.04 (+0.05%)
     
  • Dow Jones

    33,978.08
    +28.68 (+0.08%)
     
  • DAX

    15,150.03
    +17.23 (+0.11%)
     
  • Hang Seng

    22,617.77
    -71.13 (-0.31%)
     
  • NIKKEI 225

    27,455.23
    +72.67 (+0.27%)
     
  • NZD/JPY

    84.6390
    +0.3170 (+0.38%)
     

ABIONYX Pharma: Monthly Statement of Total Voting Rights and Shares Forming the Company’s Share Capital

Article L233-8-II of the French Commercial Code
Article 223-16 of the General Regulations of the AMF (French Financial Markets Authority)

PARIS, December 06, 2022--(BUSINESS WIRE)--Regulatory News:

ABIONYX Pharma (Paris:ABNX):

Market: Euronext Paris, Compartment C
ISIN code: FR0012616852

Date

Number of shares outstanding

Total voting rights

Total gross (1)

Total net (2)

November 30, 2022

28,351,774

28,351,774

28,114,613

(1) The total number of gross (or "theoretical") voting rights is used as the basis for calculating threshold crossings. In accordance with Article 223-11 of the AMF General Regulations, this number is calculated on the basis of all shares to which voting rights are attached, including those for which voting rights have been suspended.

(2) The total number of net (or "exercisable at a Shareholders’ Meeting") voting rights is calculated without taking into account shares for which voting rights have been suspended. It is released in order to ensure that the public is properly informed, in accordance with the recommendation made by the AMF on 17 July 2007.

About ABIONYX Pharma

ABIONYX Pharma is a new generation biotech company that aims to contribute to health through innovative therapies in indications where there is no effective or existing treatment, even the rarest ones. Thanks to its partners in research, medicine, biopharmaceuticals and shareholding, the company innovates on a daily basis to propose drugs for the treatment of renal and ophthalmological diseases, or new HDL vectors used for targeted drug delivery.

View source version on businesswire.com: https://www.businesswire.com/news/home/20221206005562/en/

Contacts

NewCap
Investor relations
Louis-Victor Delouvrier
Nicolas Fossiez
abionyx@newcap.eu
+33 (0)1 44 71 98 53

NewCap
Media relations
Arthur Rouillé
abionyx@newcap.eu
+33 (0)1 44 71 00 15